Transcriptomic analysis of <i>EGFR</i> co-expression and activation in glioblastoma reveals associations with its ligands
<i>BTC</i> and <i>EREG</i> are negatively associated with <i>EGFR</i> expression in GBM. These findings emphasize the role of ligands in regulating <i>EGFR</i>, where <i>EGFR</i> activation seems to be modulated by the highly varying levels of <i>EGFR</i> amplification, the sensitivity of the receptor toward ligands, and ligand expression levels. Ligand expression levels and <i>EGFR</i> mutations could refine patient stratification for EGFR-targeted therapies in GBM.
Authors
- Maurice de Wit (ORCID: https://orcid.org/0000-0003-0449-8822)
- Koen J. A. Verhagen (ORCID: https://orcid.org/0000-0001-7232-4352)
- Martin J. van den Bent (ORCID: https://orcid.org/0000-0001-5710-5127)
- Santoesha A. Ghisai (ORCID: https://orcid.org/0000-0002-3289-4294)
- Pim J. French (ORCID: https://orcid.org/0000-0002-0668-9529)
- Levi van Hijfte (ORCID: https://orcid.org/0000-0002-1402-6784)
- Nastaran Barin
- Youri Hoogstrate (ORCID: https://orcid.org/0000-0003-2166-0676)
Institutions
- Erasmus MC Cancer Institute (NL)
- Delft University of Technology (NL)
Publication Details
- Journal
- Neuro-Oncology Advances
- Published
- 2024-12-28
- DOI
- https://doi.org/10.1093/noajnl/vdae229
- Citations
- 2
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.88
Funders
- Brain Tumour Charity